A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice

American Journal of Pathology

Volumn 170, Issue 4, 2007, Pages 1325-1336

  Yang, Wan Lin ^a   Cai, Kathy Qi ^a   Smedberg, Jennifer L ^a   Smith, Elizabeth R ^a   Klein Szanto, Andres ^a   Hamilton, Thomas C ^a   Xu, Xiang Xi ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ALERTNESS; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GENE DOSAGE; GERM CELL; LIPOGENESIS; MORPHOLOGY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; OVARY; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WEIGHT REDUCTION; ADENOMA; AGING; ANIMAL; C57BL MOUSE; CELL TRANSFORMATION; DRUG EFFECT; EPITHELIUM; GENETICS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INBREEDING; MALE; METABOLISM; MOUSE MUTANT; OVARY TUMOR; PATHOLOGY; WESTERN BLOTTING;

ADENOMA; AGING; ANIMALS; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EPITHELIUM; FEMALE; GENE DOSAGE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INBREEDING; INDOMETHACIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OVARIAN NEOPLASMS; OVARY; PHENOTYPE; PYRAZOLES; SULFONAMIDES;

EID: 34247874637     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.060769     Document Type: Article

References (44)

1. Gosden RG: Biology of Menopause: The Causes and Consequences of Ovarian Aging. Edited by RG Gosden. New York, Academic Press, 1985
2. Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX: Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecol Oncol 2006, 103:719-728
3. Nicosia SV: The aging ovary. Med Clin North Am 1987, 71:1-9
4. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC: Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996, 88:1810-1820
5. Mintz B: Embryological development of primordial germ-cells in the mouse: influence of a new mutation, Wj. J Embryol Exp Morphol 1957, 5:396-406
6. Dubreuil P, Rottapel R, Reith AD, Forrester L, Bernstein A: The mouse W/c-kit locus. A mammalian gene that controls the development of three distinct cell lineages. Ann NY Acad Sci 1990, 599:58-65
7. Nocka K, Tan JC, Chiu E, Chu TY, Ray P, Traktman P, Besmer P: Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: w37, Wv, W41 and W. EMBO J 1990, 9:1805-1813
8. Reith AD, Rottapel R, Giddens E, Brady C, Forrester L, Bernstein A: W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. Genes Dev 1990, 4:390-400
9. Murphy ED: Hyperplastic and early neoplastic changes in the ovaries of mice after genic deletion of germ cells. J Natl Cancer Inst 1972, 48:1283-1295
10. Eldridge JC, McPherson III JC, Mahesh VB: Maturation of the negative feedback control of gonadotropin secretion in the female rat. Endocrinology 1974, 94:1536-1540
11. Murphy ED, Beamer WG: Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the W x/W u genotype. Cancer Res 1973, 33:721-723
12. Blaakaer J, Baeksted M, Micic S, Albrectsen P, Rygaard J, Bock J: Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol Reprod 1995, 53:775-779
13. Cramer DW, Welch WR: Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983, 71:717-721
14. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK: Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997, 91:197-208
15. Davis BJ, Lennard DE, Lee CA, Tiano HF, Morham SG, Wetsel WC, Langenbach R: Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1beta. Endocrinology 1999, 140:2685-2695
16. Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ, Dey SK: Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice Endocrinology 2001, 142:3198-3206
17. Richards JS, Russell DL, Ochsner S, Espey LL: Ovulation: new dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol 2002, 64:69-92
18. Williams CS, Mann M, DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916
19. Prescott SM, Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000, 1470:M69-M78
20. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809
21. Lal G, Ash C, Hay K, Redston M, Kwong E, Hancock B, Mak T, Kargman S, Evans JF, Gallinger S: Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res 2001, 61:6131-6136
22. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R: Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60:4705-4708
23. Subbaramaiah K, Dannenberg A: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003, 24:96-102
24. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952
25. Cramer D, Harlow B, Titus-Ernstaff L, Bohlke K, Welch WR, Greenberg ER: Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998, 351:104-107
26. Sørensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA: Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003, 88:1687-1692
27. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A: Analgesic drug use and risk of ovarian cancer. Epidemiology 2006, 17:104-107
28. Smith ER, Daly MB, Xu XX: A mechanism for Cox-2 inhibitor antiinflammatory activity in chemoprevention of epithelial cancers. Cancer Epidemiol Biomarkers Prev 2004, 13:144-145
29. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995, 83:473-482
30. Smith WL, Langenbach R: Why there are two cyclooxygenase isozymes. J Clin Invest 2001, 107:1491-1495
31. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, DuBois RN: Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003, 63:906-911
32. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN, Dey SK: Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005, 65:3735-3744
33. Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK: Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 2006, 66:2527-2531
34. Balkwill F, Coussens LM: Cancer: an inflammatory link. Nature 2004, 431:405-406
35. Clevers H: At the crossroads of inflammation and cancer. Cell 2004, 118:671-674
36. Tsafriri A, Reich R: Molecular aspects of mammalian ovulation. Exp Clin Endocrinol Diabetes 1999, 107:1-11
37. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu XX, Hamilton TC: Focus on epithelial ovarian cancer. Cancer Cell 2004, 5:19-24
38. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE: Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002, 1:53-62
39. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC: Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003, 63:1389-1397
40. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY: Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003, 63:3459-3463
41. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T: Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005, 11:63-70
42. Chen CM, Chang JL, Behringer RR: Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts. Oncogene 2004, 23:7722-7725
43. Kirtikara K, Morham SG, Raghow R, Laulederkind SJ, Kanekura T, Goorha S, Ballou LR: Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J Exp Med 1998, 187:517-523
44. Wang H, Ma WG, Tejada L, Zhang H, Morrow JD, Das SK, Dey SK: Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic makeup. J Biol Chem 2004, 279:10649-10658